Table 3.

Distances in Angstroms between Pharmacophoric Points of P2Y₁ Docked Antagonists and Template Compound 2^a

compd		3′-P	5′-P	6-N
92		0.35	0.36	0.05
93		0.28	1.88	0.20
5		0.42	0.79	1.27
7		0.38	0.50	0.27
4		0.42	1.08	0.49
94		0.33	2.22	0.7
12		0.44	1.78	0.43
13		0.45	0.83	1.24
14		0.45	1.40	0.46
15		0.16	0.42	0.25
16		0.50	0.86	0.21
17		0.27	1.60	0.30
18	isomer 1	0.78	0.72	0.50
	isomer 2	0.27	1.31	0.27
19	R-config	0.10	0.81	0.15
	S-config	0.15	0.83	0.21
20	R-config	0.26	0.63	0.18
	S-config	0.08	0.54	0.10

^aCompound 2 (MRS 2279) is (1R,2S,4S,5S)-1-[(phosphato)-methyl]-4-(2-chloro-6-methylaminopurin-9-yl)bicyclo [3.1.0]-hexane-2-phosphate. Compounds are grouped as cyclic template compounds (92, 93), acyclic bisphosphates of variable chain length (0–3 methylenes) (5, 7 (MRS 2298), 4, 94), other acyclic compounds (12-15), and cyclopropyl derivatives (16-20). Compounds 92 (2′-deoxy-2-chloro-N⁶-methyladenosine-3′,5′-bisphosphate (MRS 2216), IC₅₀ 0.206 μM), 93 (phosphoric acid mono-[3-(2-chloro-6-methylaminopurin-9-yl)-2-phosphonooxymethylcyclobutyl] ester (MRS 2264), IC₅₀ 0.805 μM), and 94 (2-[3-(6-methylaminopurin-9-yl)-propyl]propane-1,3-bisphosphate, IC₅₀ >30 μM) were reported previously.^19,20